This Penny Stock Is Surging on an Nvidia Boost. Should You Buy Shares Now or Stay Far Away?

Profusa (PFSA) stock gained more than 70% on Thursday after announcing a strategic integration with Nvidia’s (NVDA) artificial intelligence (AI) stack to power its next-gen physician portal.

This new portal is designed to analyze data from PFSA’s continuous biomarker monitoring system, using the AI giant’s NeMo hardware and software to provide real-time, actionable insights for clinicians.

Despite the massive surge following Nvidia news, Profusa stock is trading only at a fraction of its price in May.

Management’s decision to build its AI-driven insight portal on NVDA’s platform could prove game-changing for PFSA stock.

Profusa’s new portal will fuse real-time biochemistry data from its Lumee sensors with electronic medical records, enabling predictive analytics and personalized care.

By leveraging Nvidia’s hardware and software stack, Profusa aims to deliver agentic clinical workflows, longitudinal health graphs, and policy-aware orchestration, all designed to improve outcomes and reduce clinician burden.

All in all, this move positions Profusa shares at the intersection of artificial intelligence and digital health, a market investors are increasingly betting on in 2025. If executed well, tapping on NVDA technology could elevate the firm’s credibility and open doors to accelerated enterprise adoption.

Despite the bullish headline and the subsequent share price surge, investors must tread with caution on PFSA as it remains a penny stock only.

This asset class is notorious for unusual volatility, very low liquidity, and increased susceptibility to price manipulation. Meanwhile, Profusa stock is not currently covered by Wall Street analysts either – meaning investors have limited access to institutional-grade research or earnings forecasts.

While the NVDA news may drive short-term momentum, long-term viability hinges on regulatory approvals, adoption rates, and the company’s ability to scale its AI infrastructure.

In short, for risk-tolerant investors, PFSA shares might offer asymmetric upside. But for most, it’s a high-risk bet better approached with caution.

On the date of publication, Wajeeh Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com